Axsome Therapeutics (AXSM) Other Operating Expenses (2022 - 2026)

Axsome Therapeutics has reported Other Operating Expenses for 6 years, with the latest figure at $16.9 million in Q1 2026.

• Quarterly Other Operating Expenses rose 31.18% year-over-year to $16.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $101.6 million (up 36.87% YoY) and the FY2025 annual result came in at $51.4 million, down 24.24% from the prior year.
• Other Operating Expenses slipped to $16.9 million in Q1 2026 per AXSM's latest filing, from $51.1 million in the prior quarter.
• Over five years, Other Operating Expenses peaked at $52.2 million in Q4 2023 and troughed at $1.0 million in Q2 2022.
• A 5-year average of $17.3 million and a median of $12.0 million in 2023 frame the typical range for Other Operating Expenses.
• The sharpest annual moves came in 2023 and 2024: Other Operating Expenses surged 1066.92% in 2023, then plunged 55.73% in 2024.
• Over 5 years, Other Operating Expenses stood at $8.1 million in 2022, then surged by 544.5% to $52.2 million in 2023, then slumped by 55.73% to $23.1 million in 2024, then jumped by 120.98% to $51.1 million in 2025, then slumped by 66.93% to $16.9 million in 2026.
• According to Business Quant data, Other Operating Expenses over the past three periods registered $16.9 million, $51.1 million, and $26.7 million for Q1 2026, Q4 2025, and Q3 2025 respectively.